1 in 4 Nonsmoking Americans is Still Exposed to Secondhand Smoke
After 2 ½ decades of progress, efforts to reduce exposure to secondhand smoke among non-smokers have stalled in the US, according to new data from the Centers for Disease Control and Prevention (CDC).
3-Time Cancer Survivor Finds Comfort at Hope Lodge
Cervical and breast cancer survivor Christine E. Sprecher needed treatment for a long-term side effect but had no place to stay until she found the American Cancer Society Hope Lodge program.
New Drug Reduces Recurrence Risk for Some Women With Early-Stage Breast Cancer
Research presented at the San Antonio Breast Cancer Symposium may result in a new standard of care for some people with HER2 positive, early stage breast cancer.
FDA Approves First Biosimilar for Non-Hodgkin Lymphoma
The US Food and Drug Administration (FDA) has approved Truxima (rituximab-abbs), the first biosimilar drug to treat adults with some types of non-Hodgkin lymphoma.
Six Plan-ahead Tips to Party Smarter
Have a jolly, festive time at holiday parties this month while sticking to your healthy eating goals. Follow our tips to enjoy the season without having to pay for it later.
Nurture Your Emotional Health
Taking care of yourself emotionally can help you feel better and work better. Find out what you can do to stay positive and happy.
Can Coffee Lower Cancer Risk?
What’s the latest about the health effects of that morning-boosting, belly-warming cup of rich, creamy coffee? We’ll tell you what the research says about coffee and your cancer risk.
FDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
